(January 24, 2024, 3:51 PM EST) -- WASHINGTON, D.C. — The U.S. Food and Drug Administration and Danco Laboratories LLC, the manufacturer of Mifeprex-brand mifepristone, on Jan. 23 filed separate opening briefs in the U.S. Supreme Court, arguing that the Fifth Circuit U.S. Court of Appeals erred in upholding a district court’s stay of the Food and Drug Administration’s 2016 amendments to mifepristone’s approval and the agency’s 2021 decision not to enforce its regulations during the COVID-19 pandemic....